Join the club for FREE to access the whole archive and other member benefits.

Thomas E. Hughes

President and CEO at Navitor Pharmaceuticals.

Dr. Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Prior to joining Navitor, Dr. Hughes served as President and Chief Scientific Officer of Zafgen and previously led Zafgen as CEO from 2008 to 2017. During this time, Dr. Hughes established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Dr. Hughes held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Dr. Hughes currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.

Visit website: http://www.navitorpharma.com/thomas-e-hughes-phd/

 tom-hughes-04b514

 TEHughes2009

See also: Company Navitor Pharmaceuticals - Company developing medicines designed to target specific nutrient-sensing proteins to treat diseases.

Thomas E. Hughes is also referenced in the following:

Longevity Leaders World Congress 2021

04-May-2021 to 07-May-2021

The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).

Thomas E. Hughes News

Super summary of 3rd Annual Longevity Therapeutics Summit

Lifespan.io (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Read more...